Clinical-stage biopharmaceutical company DBV Technologies (NASDAQ:DBVT) announced a financing of up to $306.9M (€284.5M), including gross proceeds of $125.5M (€116.3M) to be received upon closing and an aggregate of up to ($181.4M) (€168.2M) in gross proceeds if all the warrants are exercised.
DBV Technologies, a French biotech working on a treatment for food allergies, says it's running out of cash.
The disclosure came via a going concern note in the company’s fourth-quarter and full-year 2023 earnings report on Friday, with DBV saying it doesn’t have enough money to keep the lights on for a full 12 months.
Novartis appears to be throwing in the towel on its Xolair-successor hopeful. The Swiss pharma’s Phase III peanut allergy trial for ligelizumab has been terminated, according to a ClinicalTrials.gov update Tuesday.
After lackluster sales dampened the initial enthusiasm that came with a $2.1 billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia.
Nestlé has divested Palforzia to U.S.-based allergy specialist Stallergenes Greer for an undisclosed sum, the food giant said Tuesday.
A trial investigating desensitisation immunotherapy delivered as toothpaste for adults with peanut allergy reached a final milestone after Intrommune Therapeutics completed the last patient’s last visit.
The Phase I OMEGA clinical trial (NCT04603300) is a multi-centre, randomised, placebo-controlled double-blind study involving splitting 32 participants with peanut allergy into two groups to receive either an escalating dose of the company’s candidate INT301 or placebo.
A small, Eli Lilly-backed biotech has received $40 million on its way to the clinic with a self-administered injection for peanut allergies.
IgGenix unveiled a Series B round on Monday to support what CEO Jessica Grossman calls a “revolutionary” approach to preventing both food and non-food allergies, from dairy to dust to dogs.
Nestlé announced Tuesday it will unload the world's only approved peanut allergy treatment just two years after acquiring the company that developed it. Potential patients must've found it easier to just not eat at Five Guys and Texas Roadhouse.
The FDA has grounded DBV Technologies’ latest phase 3 peanut allergy clinical trial before it even had a chance to take flight. Just weeks after DBV trumpeted the finalization of the protocol, the FDA has placed a partial clinical hold on the study and requested changes to the design of the study.
DBV Technologies has chalked up a win for its beleaguered peanut allergy patch candidate, hitting the primary endpoint in a phase 3 clinical trial in infants to send its battered share price past its prior high for 2022.
Children in England with peanut allergies could be among the first in Europe to get access to Aimmune’s oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS England.